PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

For PSMA+ mCRPC after hormone therapy,

THERE'S

PLUVICTO



Every day without progression is a VICTORY.

Men who received PLUVICTO **saw more time without their cancer progressing**, with a median of **9.3 months** vs **5.6 months** with a second hormone therapy.

49% of men who received PLUVICTO saw their tumors shrink or disappear (vs **14%**).

NOW AVAILABLE *before* CHEMOTHERAPY*

*For certain men as determined by their doctor.

Actor portrayal.

Guidance along your journey with PLUVICTO

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information on pages 27-28.

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

MENU

It's normal to have questions when starting a new treatment, especially when it works differently than other treatments.

This guide can answer questions you may have about treatment with PLUVICTO.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 27-28.

If your prostate cancer is progressing,

IS IT TIME FOR SOMETHING DIFFERENT?

After all you and your loved ones have been through, you know that **every treatment matters**.



If your cancer has spread outside the prostate and no longer responds to hormone treatment that lowers testosterone, PLUVICTO could be right for you.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 27-28.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

Please see additional Important Safety Information on pages 27-28.

WHAT IS PLUVICTO?

PLUVICTO is not chemotherapy. It's the FIRST and ONLY RLT for PSMA+ mCRPC.

Radioligand therapy (RLT) is a different type of radiation therapy that is injected or infused and targets a biomarker called PSMA. PLUVICTO is designed to find and attack PSMA+ cells, including cancer cells.*

*May also damage healthy PSMA+ and other nearby cells.

Remember it in 3 steps:



Artist interpretation.

PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells.



When PLUVICTO finds PSMA on the surface of a cell, it goes into the cell.



Once inside, PLUVICTO releases radiation, damaging or destroying the cell from within. It may also affect some nearby healthy cells.

You can find out if you are PSMA+ by having an imaging test called a PSMA-PET scan.

mCRPC, metastatic castration-resistant prostate cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see additional Important Safety Information on pages 27-28.

PLUVICTO may give you
MORE TIME
WITHOUT
PROGRESSION.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY

PLUVICTO gave men more
TIME WITHOUT CANCER WORSENING

Radiographic Progression-Free Survival (rPFS)

9.3 MONTHS for men treated with PLUVICTO
vs 5.6 MONTHS for men on a 2nd hormone therapy

Updated analysis
17 MONTHS LATER*

11.6 MONTHS
PLUVICTO
(234 men evaluated)

vs

5.6 MONTHS
2nd hormone therapy
(234 men evaluated)

*Additional analysis conducted to learn more about rPFS in PLUVICTO patients.

The PSMAfore clinical trial measured rPFS. Median rPFS is the time when half of the men in the study were still alive without their cancer spreading or getting worse.

The PSMAfore trial included 468 men with PSMA+ prostate cancer that spread outside their prostate. They were divided into 2 groups:

- 234 men were treated with PLUVICTO
  - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 234 men were treated with a second hormone therapy

Overall survival (OS)

Median OS was higher in patients who had PLUVICTO (24.5 months) compared to patients on a second hormone therapy (23.1 months). These results were not statistically significant.

IMPORTANT SAFETY INFORMATION (continued)

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY

With PLUVICTO, more than triple the men had TUMORS SHRINK OR DISAPPEAR

Overall Response Rate (ORR)*

49%
PLUVICTO
(72 men evaluated)

vs

14%
2nd hormone therapy
(72 men evaluated)

The PSMAfore trial measured ORR, which measures the impact of PLUVICTO on tumors. It includes both complete response (CR) and partial response (PR).

- CR: **21%** with PLUVICTO vs **2.8%** with a second hormone therapy
- PR: **28%** with PLUVICTO vs **11%** with a second hormone therapy

*Measuring ORR was not the main goal of the PSMAfore trial. It was not statistically significant. It does not impact the results for rPFS.



IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY

PSA RESPONSE

With PLUVICTO, more men had their PSA LEVEL DROP

Prostate-Specific Antigen (PSA) Response*

Percentage of men who had at least a 50% drop in PSA

51%
PLUVICTO
(217 men evaluated)

VS

17%
2nd hormone therapy
(225 men evaluated)

If PSA was 100 ng/mL before the clinical trial, then PSMAfore would measure the PSA level if it dropped to 50 ng/mL or lower.*

*Measuring PSA response was not the main goal of the PSMAfore trial. It was not statistically significant. It does not impact the results for rPFS.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 27-28.

A chance for MORE EVERYDAY VICTORIES.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY AND CHEMOTHERAPY

Men taking PLUVICTO LIVED LONGER

Overall Survival (OS)

15 MONTHS
PLUVICTO plus standard therapy
(551 men evaluated)

VS

11 MONTHS
Standard therapy alone
(280 men evaluated)

The VISION clinical trial measured OS. Median OS is the length of time half of the men in the study were still alive.

Results have been rounded from 15.3 to 15 months and 11.3 to 11 months.

The VISION trial included 831 men with PSMA+ prostate cancer that spread outside their prostate. They were divided into 2 groups:

- 551 men were treated with PLUVICTO plus standard therapy*
  - PLUVICTO was given once every 6 weeks for up to 6 treatments
- 280 men were treated with standard therapy alone

*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (^{223}Ra), or drugs still being studied.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY AND CHEMOTHERAPY



PLUVICTO gave men over twice the amount of

TIME WITHOUT CANCER WORSENING

Radiographic Progression-Free Survival (rPFS)

9 MONTHS
PLUVICTO plus standard therapy
(385 men evaluated)

VS

3.5 MONTHS
Standard therapy alone
(196 men evaluated)

The VISION clinical trial measured rPFS. Median rPFS is the time when half of the men in the study were still alive without their cancer spreading or getting worse.*

Results have been rounded from 8.7 to 9 months and 3.4 to 3.5 months.

*rPFS results may be misread. In the clinical trial, many patients treated with standard therapy alone dropped out early, so the PLUVICTO-treated patients provided more information.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

Please see additional Important Safety Information on pages 27-28.

PLUVICTO may help you

LIVE LONGER,

giving you the chance for more everyday victories.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY AND CHEMOTHERAPY



With PLUVICTO, more men had TUMORS SHRINK OR DISAPPEAR

Overall Response Rate (ORR)

49%
PLUVICTO plus standard therapy
(184 men evaluated)

vs

1.6%
Standard therapy alone
(64 men evaluated)

The VISION trial also measured ORR, which measures the impact of PLUVICTO on tumors. It includes complete response (CR) and partial response (PR).

- CR: **9%** with PLUVICTO vs **0%** with standard therapy
- PR: **40%** with PLUVICTO vs **1.6%** with standard therapy

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

Please see additional Important Safety Information on pages 27-28.

CLINICAL TRIAL RESULTS: AFTER HORMONE THERAPY AND CHEMOTHERAPY

PSA RESPONSE

With PLUVICTO, more men had their **PSA LEVEL DROP**

Prostate-Specific Antigen (PSA) Response*

Percentage of men who had at least a 50% drop in PSA

46%
PLUVICTO plus standard therapy
(385 men evaluated)

vs

7%
Standard therapy alone
(196 men evaluated)

If PSA was 100 ng/mL before the clinical trial, then VISION would measure the PSA level if it dropped to 50 ng/mL or lower.*

*Measuring PSA response was not the main goal of the VISION trial. It was not statistically significant. It does not impact the results for OS or rPFS.

IMPORTANT SAFETY INFORMATION (continued)

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information on pages 27-28.

PLUVICTO is given in up to 6 DOSES

Each dose:

- Will be given in 1 of 2 ways: through an intravenous (IV) injection or infusion
- Is given once every 6 weeks

PLUVICTO

One dose every 6 weeks for up to 6 treatment cycles



Over 20,000 men have already taken PLUVICTO

PLAN AHEAD
Find treatment centers in your area
or visit PLUVICTO.com

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

Please see additional Important Safety Information on pages 27-28.

What to expect

BEFORE EACH DOSE

Your health care team

While on treatment with PLUVICTO, a team of doctors will work together to make sure you are taken care of. You will also get support from nurses and other health professionals.

Below are doctors who may be a part of your care team:

- **A medical oncologist,** who treats cancer with chemotherapy, hormone therapy, and immunotherapy
- **A urologist,** who treats urinary system and male reproductive system diseases
- **A radiation oncologist,** who treats cancer with radiation therapy
- **A nuclear medicine doctor,** who focuses on diagnosing and treating diseases using radioactive materials

Explore more of what you can expect while on treatment with PLUVICTO.

Visit PLUVICTO.com for more resources and information.

IMPORTANT SAFETY INFORMATION (continued)

What is the most important information I should know about PLUVICTO? (continued)

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 27-28.

What to expect THROUGHOUT TREATMENT

Lab tests

You will continue to have some tests done, like blood work, before and during treatment. Your first test will be performed a few days before your first dose with PLUVICTO.



Hydrating

Drink plenty of water before and after each dose. This will help get rid of extra radiation in your body.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 27-28.

What to expect
AFTER EACH DOSE

Reduce radiation exposure

Your body, blood, and urine give off radiation for a while after getting PLUVICTO. Always follow your doctor's instructions. Also, here are some tips to help reduce overall exposure to yourself and others:

Distancing

Limit close contact (less than 3 feet) with others after each dose. Stay apart longer from some higher-risk groups. Ask your doctor for more information.

Stay hydrated and urinate (pee) as much as you can

Sleep in a separate bedroom

No sexual activity for 7 days. Use protection after that

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including (continued):

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see additional Important Safety Information on pages 27-28.

Understanding PLUVICTO
SIDE EFFECTS

It's normal to have concerns about side effects when starting a new treatment. Speak with your care team about any side effects you may be experiencing. You should also ask any questions you may have.

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Talk to your CARE TEAM.

Your health care provider may temporarily delay your next dose, decrease your dose, or completely stop your treatment with PLUVICTO if you develop certain serious side effects.

Please see Important Safety Information on pages 27-28.

Talk to your HEALTH CARE TEAM if you have questions about treatment with PLUVICTO.

Please see Important Safety Information on pages 27-28.

Understanding TARGETED RADIATION

You may have questions about the targeted radiation from PLUVICTO. Learning about it could help you better plan your journey.

Radiation from PLUVICTO does not stay in your body long.

Within 2 days, over half of the radiation will leave your body.
Within about 14 days, most of the radiation (>99%) will be gone.

Radiation exposure to others is about the same as 3 flights.

After one dose of PLUVICTO, a care partner may be exposed to the same amount of radiation as 3 flights from the East Coast to the West Coast of the United States.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

Please see additional Important Safety Information on pages 27-28.

IMPORTANT SAFETY INFORMATION (continued)

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information on pages 27-28.

COVERAGE

When you and your health care provider have decided it's time for you to start treatment with PLUVICTO, here's what you'll need to know about PLUVICTO coverage.

PLUVICTO may be accessible to most insured men*

More than **80%** of insured men benefited from coverage for PLUVICTO as of January 2025

The other 20% of men do not have available policies and/or situations may be decided on an individual basis. Follow up with your plan to determine your coverage.

More than **8 out of 10** men covered paid $0 out of pocket per infusion

This is based on a study from 2023 to 2024. Approximately 85% of patients in the study paid $0 for PLUVICTO. Out-of-pocket costs for PLUVICTO for remaining patients vary. It may be as high as the full price of the product. There may also be added costs related to treatment, including but not limited to administration fees.

*This is not a guarantee of coverage. Patient out-of-pocket costs may vary. Coverage and reimbursement decisions vary.

This coverage data comes from patients who had taken hormone therapy and chemotherapy.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

Please see additional Important Safety Information on pages 27-28.

NOVARTIS PATIENT SUPPORT™

Once you and your health care provider decide to begin PLUVICTO, Novartis Patient Support is here to help.

We can help you:

Navigate the insurance process

Get financial support*

Find answers to questions across the treatment journey

If you have already been prescribed PLUVICTO, sign up for Novartis Patient Support.

Call 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays. Ask your health care provider to help you sign up for assistance.

Get financial support*

If you have private insurance, you could be eligible for Co-Pay Plus and **pay as little as $0** for your PLUVICTO treatment.

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare, Medicaid, or any other federal or state program. Offer subject to a maximum benefit per course of treatment. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms and Conditions in the enrollment forms for details.

IMPORTANT SAFETY INFORMATION (continued)

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Please see additional Important Safety Information on pages 27-28.

IMPORTANT SAFETY INFORMATION

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

PLUVICTO may cause serious side effects, including:

Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:

- Tiredness or weakness
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal or difficulty stopping bleeding
- Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers

Kidney problems. You should stay well-hydrated before and after treatment. Tell your doctor right away if you develop any new or worsening urinary symptoms.

All radiopharmaceuticals, including PLUVICTO, have the potential to **cause harm to an unborn baby.**

- You should use effective contraception during treatment with PLUVICTO and for 14 weeks after your last dose

PLUVICTO may cause temporary or permanent **infertility.**

Please see full Prescribing Information here.

IMPORTANT SAFETY INFORMATION (continued)

The most common side effects of PLUVICTO include:

- Decreased blood cell counts
- Tiredness
- Dry mouth
- Nausea
- Appetite loss
- Joint pain
- Constipation
- Back pain

These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information here.

GLOSSARY

Understanding key terms related to your treatment is important. It will help you know what to expect while taking PLUVICTO and can also help you communicate with your care team.

Term	Definition
Biomarker *(page 6)*	Something that can tell your doctor more about your cancer.
Chemotherapy *(pages 1, 4, 6, 12, 13, 15, 16, 18, 25)*	Treatment that uses chemicals to kill fast-growing cells in the body.
Complete response (CR) *(pages 9, 15)*	When tumors disappear with treatment.
Hormone therapy *(pages 1, 4, 8-10, 12, 13, 15, 16, 18, 25)*	Treatment that interferes with the effects of testosterone.
Metastatic castration-resistant prostate cancer (mCRPC) *(pages 1, 6)*	A type of advanced prostate cancer that has spread outside the prostate. It also no longer responds as well to certain hormone treatments.
Overall response rate (ORR) *(pages 9, 15)*	The total percentage of patients whose cancer responds to treatment. Their tumors disappear or shrink in size.
Overall survival (OS) *(pages 8, 12, 16)*	Measure of how long patients live after they are assigned treatment in a clinical trial.
Partial response (PR) *(pages 9, 15)*	When a treatment decreases a tumor's size.

Please see Important Safety Information on pages 27-28.

GLOSSARY (continued)

Term	Definition
Prostate-specific antigen (PSA) *(pages 10, 16)*	A substance made by the prostate that may be found in higher-than-normal levels in the blood of men who have prostate cancer. PSA levels are found through a blood test.
Prostate-specific membrane antigen (PSMA) *(pages 1, 6, 8, 12)*	A biomarker commonly found on the outside of prostate cancer cells and some normal cells. A PSMA-PET scan can find PSMA+ cells in your body.
PSMA-PET scan *(page 6)*	An imaging test that can help find PSMA+ cells, including prostate cancer cells, in your body.
Radiographic progression-free survival (rPFS) *(pages 8-10, 13, 16)*	In a clinical trial, how long patients live without their cancer getting worse. It is determined by imaging tests.

Please see Important Safety Information on pages 27-28.

PLUVICTO

Stay in touch with your health care team.

How will you make today a victory?

Learn how Novartis can support you throughout your treatment.
Sign up for Novartis Patient Support.

Call 1-844-638-7222, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays.

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with:

- hormone therapy or
- hormone therapy and chemotherapy

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer. Drink plenty of water and urinate as often as possible during the first hours after administration.

To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days. Refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

4/25 FA-11395374

PLUVICTO®
lutetium Lu 177 vipivotide tetraxetan
INJECTION FOR INTRAVENOUS USE

Please see additional Important Safety Information on pages 27-28.